Skip to main content

Challenging Times Ahead for Boeing Stock; 5-Star Analyst Slashes Price Target

Challenging Times Ahead for Boeing Stock; 5-Star Analyst Slashes Price TargetIt has been a rollercoaster month for investors of beleaguered airline Boeing (BA). To recap: the stock dropped during the first three weeks of March all the way down to $95 per share, an amazing loss of 66%. However, last week’s relief rally saw the share price reclaiming 70% of its value. Will the volatility continue? Possibly, as there are currently a wide variable of unknowns concerning the A&D giant’s future.Nevertheless, Credit Suisse’s Robert Spingarn slashed his price target on Boeing shares to $187 (from $367), which still implies about 23% upside from current levels. Despite the profit potential, the analyst can't quite see his way clear to actually recommending "buying" BA stock, assigning the shares only a "neutral" rating. (To watch Spingarn’s track record, click here)Questions have been raised concerning Boeing’s financial health, following a request for $60 billion in federal aid to assist its ailing ecosystem. Last week’s developments, along with the dividend cut and the firm’s latest modeling, leave the 5-star analyst “reasonably confident in BA’s ability to contain near term liquidity/dilution risks.”The larger concern for Spingarn remains the “highly uncertain landscape for the OE recovery in ‘21+.”The analyst notes that revenue passenger kilometer (RPK) recovery in H1’21 could be impacted by further COVID-19 mitigation actions. Looking further ahead to H2’21 and beyond, along with a possible reduced demand for business travel due to the rising popularity of video conferencing, the financial impact of the coronavirus on consumers’ leisure spending power could further impact RPK recovery.And although lower fuel prices could translate into lower ticket prices, offering a counter relief to the aforementioned issues, Spingarn reminds investors that there are further complications. “Low oil improves the unit economics of operating older aircraft, disincentivizing the purchase of new tails. At the same time, MAX delays offer some airlines a contractual escape to cancel orders—a bad combo for BA. And while demand for new aircraft could be challenged for years, the near term nevertheless promises a boost for supply as MAX returns to service. BCA’s end-market could therefore be facing a dual supply/demand shock which may result in an extended period of indigestion and “lower for longer” production rates,” the analyst said.Among other Street analysts, Boeing currently holds a Moderate Buy consensus rating based on 6 Buys, 13 Holds and 1 Sell. At $211, the average price target promises returns in the shape of 39%, should the figure be met in the months ahead. (See Boeing stock analysis on TipRanks) More recent articles from Smarter Analyst: * When Will Apple’s 5G-Enabled iPhone 12 Launch? Analyst Weighs In * Don’t Buy Roku Stock, Says Analyst; The 'Coming Recession' Is a Risk * Cytosorbents's Blood Purification Technology Could Play Important Role in Fighting COVID-19; Analyst Says 'Buy' * 2 "Strong Buy" Stocks with Solid Long-Term Upside




from Yahoo Finance https://ift.tt/2X1Yoet

Labels:

Comments

Post a Comment

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $
Post a Comment
Read more

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be
Post a Comment
Read more